• Publications
  • Influence
Pegaptanib for neovascular age-related macular degeneration.
BACKGROUND Pegaptanib, an anti-vascular endothelial growth factor therapy, was evaluated in the treatment of neovascular age-related macular degeneration. METHODS We conducted two concurrent,Expand
  • 2,022
  • 93
  • PDF
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies.
Age-related macular degeneration is the principal cause of registered legal blindness among those aged over 65 in the United States, western Europe, Australia, and Japan. Despite intensive research,Expand
  • 841
  • 53
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Aptamers are oligonucleotide ligands that are selected for high-affinity binding to molecular targets. Pegaptanib sodium (Macugen; Eyetech Pharmaceuticals/Pfizer) is an RNA aptamer directed againstExpand
  • 1,088
  • 42
  • PDF
A central role for inflammation in the pathogenesis of diabetic retinopathy
Diabetic retinopathy is a leading cause of adult vision loss and blindness. Much of the retinal damage that characterizes the disease results from retinal vascular leakage and nonperfusion. DiabeticExpand
  • 942
  • 40
Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy.
The vitreous levels of the angiogenic polypeptide vascular endothelial growth factor (also known as vascular permeability factor) were measured and compared in eyes with and without proliferativeExpand
  • 782
  • 34
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.
PURPOSE Assess 12-month efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema after branch retinal vein occlusion (BRVO). DESIGN Prospective,Expand
  • 354
  • 30
  • PDF
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.
PURPOSE To report 36-month outcomes of RIDE (NCT00473382) and RISE (NCT00473330), trials of ranibizumab in diabetic macular edema (DME). DESIGN Phase III, randomized, multicenter, double-masked,Expand
  • 612
  • 29
  • PDF
Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.
OBJECTIVE To evaluate the safety and efficacy of intravitreal injections of an antigen-binding fragment of a recombinant humanized monoclonal antibody directed toward vascular endothelial growthExpand
  • 563
  • 29
  • PDF
Leukocyte-mediated endothelial cell injury and death in the diabetic retina.
Endothelial cell death is a hallmark of diabetic retinopathy. Its occurrence is required for the formation of acellular (devitalized) capillaries, lesions that produce irreversible retinal ischemiaExpand
  • 480
  • 22